<p>Caris Life Sciences, Inc.（纳斯达克代码：CAI - 获取免费报告）在周六的交易中创下了 52 周新低，此前花旗集团将该股的目标价从 35.00 美元下调至 28.00 美元。花旗集团目前对该股维持买入评级。Caris Life Sciences 的股价最低曾达到 15.71 美元，最后交易价为 16.15 美元，成交量为 8867526 股。该股此前收盘价为 19.84 美元。</p>
<p>获取 <strong>Caris Life Sciences</strong> 的提醒：</p>
<p>其他几位股票研究分析师最近也对该股发布了报告。Piper Sandler 在 4 月 10 日的研究报告中开始覆盖 Caris Life Sciences 的股票。他们为该公司设定了 “中性” 评级和 21.00 美元的目标价。华尔街 Zen 在 5 月 2 日的研究报告中将 Caris Life Sciences 的评级从 “买入” 下调至 “持有”。BTIG Research 在周五的报告中将 Caris Life Sciences 的目标价从 38.00 美元下调至 32.00 美元，并为该公司设定了 “买入” 评级。摩根大通在周五的研究报告中将 Caris Life Sciences 的目标价从 35.00 美元下调至 30.00 美元，并对该股设定了 “增持” 评级。最后，Robert W. Baird 在周五的报告中为 Caris Life Sciences 设定了 22.00 美元的目标价。六位分析师对该股给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股目前的共识评级为 “适度买入”，共识目标价为 27.56 美元。</p>
<p><strong>查看我们关于 Caris Life Sciences 的最新研究报告</strong></p>
<h2>影响 Caris Life Sciences 的关键故事</h2>
<p>以下是本周影响 Caris Life Sciences 的关键新闻：</p>
<ul>
<li>积极情绪：Caris 报告了 2026 年第一季度强劲的业绩，总收入同比增长 79%，达到 2.162 亿美元，显示出其分子分析服务的持续需求。Caris Life Sciences 发布 2026 年第一季度财务业绩</li>
<li>积极情绪：该公司向纽约州卫生监管机构提交了申请，申请授权在纽约样本上进行 Caris Assure 血液检测，这可能是其诊断平台的一个重要商业扩展。Caris Life Sciences 向纽约州卫生部提交 Caris Assure 血液检测授权申请</li>
<li>积极情绪：尽管下调了目标价，花旗、摩根大通和 BTIG 仍对 CAI 保持乐观评级，表明分析师仍然认为当前水平有显著上行空间。Benzinga 分析师更新</li>
<li>中性情绪：投资者仍在解析财报电话会议的记录和演示，关注盈利能力、利润趋势以及管理层的全年指引是否可实现。Caris（CAI）2026 年第一季度财报电话会议记录</li>
<li>中性情绪：关于该股下跌的报道反映出更广泛的担忧，即估值仍然偏高，市场可能更关注预期和指引，而非强劲的收入超预期。为什么 Caris Life Sciences, Inc.（CAI）的股价下跌了 18.04%</li>
<li>消极情绪：多位分析师在报告后下调了目标价，包括花旗至 28 美元、摩根大通至 30 美元和 BTIG 至 32 美元，这可能对情绪产生了影响，尽管所有分析师都维持了积极评级。分析师目标价变动</li>
</ul>
<h2>Caris Life Sciences 的机构交易</h2>
<p>对冲基金和其他机构投资者最近修改了对该股的持仓。瑞银集团在第四季度将其在 Caris Life Sciences 的持仓增加了 825.9%。瑞银集团目前拥有 2183980 股该公司的股票，价值 58924000 美元，此前在上个季度购买了 1948107 股。Zevenbergen Capital Investments LLC 在第四季度新建了对 Caris Life Sciences 的持仓，价值约 14655000 美元。德凯银行在第四季度购买了价值约 3942000 美元的 Caris Life Sciences 新股份。Hamilton Lane Advisors LLC 在第四季度新建了对 Caris Life Sciences 的持仓，价值约 1584000 美元。最后，TD Waterhouse Canada Inc.在第四季度新建了对 Caris Life Sciences 的持仓，价值约 2498000 美元。</p>
<h2>Caris Life Sciences 的价格表现</h2>
<p>该股市值为 45.6 亿美元，市盈率为-2.12。该公司的 50 日简单移动平均线为 19.15 美元。公司的债务与股本比率为 0.66，流动比率为 7.85，速动比率为 7.35。</p>
<p>Caris Life Sciences（纳斯达克代码：CAI - 获取免费报告）最后一次发布季度财报是在 2 月 26 日，报告显示该季度每股收益（EPS）为 0.28 美元，超出市场共识预期的 0.01 美元，超出幅度为 0.27 美元。Caris Life Sciences 的净利润率为 3.75%，股本回报率为 102.71%。该公司该季度的收入为 2.9289 亿美元，而分析师预期为 2.81 亿美元。在去年同期，该公司的每股收益为-1.73 美元。该公司的季度收入同比增长 125.4%。分析师预计 Caris Life Sciences, Inc.在本财年将发布 0.12 美元的每股收益。</p>
<h2>关于 Caris Life Sciences</h2>
<p>（获取免费报告）</p>
<p>Caris Life Sciences（纳斯达克代码：CAI）是一家分子科学公司，专注于推动肿瘤学中的精准医学。该公司开发并提供全面的分子分析服务，旨在识别 DNA、RNA 和蛋白质模式中的可操作生物标志物。其临床服务旨在通过根据肿瘤生物学将患者与靶向疗法、免疫疗法和相关临床试验匹配，来支持肿瘤科医生的治疗决策。</p>
<p>Caris 提供基于实验室的诊断测试和相关的解释报告，将高通量测序和其他分子技术与生物信息学分析相结合。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Caris Life Sciences</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Caris Life Sciences 吗？</h2>
<p>在考虑 Caris Life Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Caris Life Sciences 并不在名单上。</p>
<p>虽然 Caris Life Sciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

<p>Caris Life Sciences (NASDAQ:CAI) 在被花旗集团将其目标价从 35 美元下调至 28 美元后，达到了 15.71 美元的新 52 周低点，同时维持了买入评级。其他分析师也调整了他们的目标，Piper Sandler 将其评级设定为中性，目标价为 21 美元，而摩根大通则将目标价下调至 30 美元。尽管评级下调，该股票的共识评级为 “适度买入”，目标价为 27.56 美元。该公司报告了 2026 年第一季度强劲的业绩，收入同比增长 79%，显示出对其服务的持续需求</p>

<p>Shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) hit a new 52-week low during trading on Saturday after Citigroup lowered their price target on the stock from $35.00 to $28.00. Citigroup currently has a buy rating on the stock. Caris Life Sciences traded as low as $15.71 and last traded at $16.15, with a volume of 8867526 shares. The stock had previously closed at $19.84.</p>
<div class="lb-trans"><p>Caris Life Sciences, Inc.（纳斯达克代码：CAI - 获取免费报告）在周六的交易中创下了 52 周新低，此前花旗集团将该股的目标价从 35.00 美元下调至 28.00 美元。花旗集团目前对该股维持买入评级。Caris Life Sciences 的股价最低曾达到 15.71 美元，最后交易价为 16.15 美元，成交量为 8867526 股。该股此前收盘价为 19.84 美元。</p>
</div><p>Get <strong>Caris Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Caris Life Sciences</strong> 的提醒：</p>
</div><p>Several other equities research analysts also recently issued reports on the stock. Piper Sandler assumed coverage on shares of Caris Life Sciences in a research report on Friday, April 10th. They set a &#34;neutral&#34; rating and a $21.00 price objective for the company. Wall Street Zen cut shares of Caris Life Sciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, May 2nd. BTIG Research lowered their target price on Caris Life Sciences from $38.00 to $32.00 and set a &#34;buy&#34; rating for the company in a report on Friday. JPMorgan Chase &amp; Co. dropped their price target on Caris Life Sciences from $35.00 to $30.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday. Finally, Robert W. Baird set a $22.00 price target on Caris Life Sciences in a report on Friday. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $27.56.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对该股发布了报告。Piper Sandler 在 4 月 10 日的研究报告中开始覆盖 Caris Life Sciences 的股票。他们为该公司设定了 “中性” 评级和 21.00 美元的目标价。华尔街 Zen 在 5 月 2 日的研究报告中将 Caris Life Sciences 的评级从 “买入” 下调至 “持有”。BTIG Research 在周五的报告中将 Caris Life Sciences 的目标价从 38.00 美元下调至 32.00 美元，并为该公司设定了 “买入” 评级。摩根大通在周五的研究报告中将 Caris Life Sciences 的目标价从 35.00 美元下调至 30.00 美元，并对该股设定了 “增持” 评级。最后，Robert W. Baird 在周五的报告中为 Caris Life Sciences 设定了 22.00 美元的目标价。六位分析师对该股给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股目前的共识评级为 “适度买入”，共识目标价为 27.56 美元。</p>
</div><p><strong>View Our Latest Research Report on Caris Life Sciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Caris Life Sciences 的最新研究报告</strong></p>
</div><h2>Key Stories Impacting Caris Life Sciences</h2>
<div class="lb-trans"><h2>影响 Caris Life Sciences 的关键故事</h2>
</div><p>Here are the key news stories impacting Caris Life Sciences this week:</p>
<div class="lb-trans"><p>以下是本周影响 Caris Life Sciences 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Caris reported strong Q1 2026 results, with total revenue rising 79% year over year to $216.2 million, signaling continued demand for its molecular profiling services. Caris Life Sciences Reports First Quarter 2026 Financial Results</li>
<li>Positive Sentiment: The company submitted an application to New York State health regulators for authorization to perform Caris Assure blood-based testing on New York specimens, a potentially meaningful commercial expansion for its diagnostic platform. Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization</li>
<li>Positive Sentiment: Despite lowering price targets, Citigroup, JPMorgan, and BTIG all kept bullish ratings on CAI, suggesting analysts still see substantial upside from current levels. Benzinga analyst update</li>
<li>Neutral Sentiment: Investors are still parsing the earnings call transcript and presentation for details on profitability, margin trends, and whether management’s full-year guidance is achievable. Caris (CAI) Q1 2026 Earnings Call Transcript</li>
<li>Neutral Sentiment: Coverage focused on why the stock is down reflects broader concern that valuation remains elevated and that the market may be reacting more to expectations and guidance than to the strong revenue beat. Why Caris Life Sciences, Inc.’s (CAI) Stock Is Down 18.04%</li>
<li>Negative Sentiment: Multiple analysts cut their price targets after the report, including Citigroup to $28, JPMorgan to $30, and BTIG to $32, which may have weighed on sentiment even though all maintained positive ratings. Analyst price target changes</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Caris 报告了 2026 年第一季度强劲的业绩，总收入同比增长 79%，达到 2.162 亿美元，显示出其分子分析服务的持续需求。Caris Life Sciences 发布 2026 年第一季度财务业绩</li>
<li>积极情绪：该公司向纽约州卫生监管机构提交了申请，申请授权在纽约样本上进行 Caris Assure 血液检测，这可能是其诊断平台的一个重要商业扩展。Caris Life Sciences 向纽约州卫生部提交 Caris Assure 血液检测授权申请</li>
<li>积极情绪：尽管下调了目标价，花旗、摩根大通和 BTIG 仍对 CAI 保持乐观评级，表明分析师仍然认为当前水平有显著上行空间。Benzinga 分析师更新</li>
<li>中性情绪：投资者仍在解析财报电话会议的记录和演示，关注盈利能力、利润趋势以及管理层的全年指引是否可实现。Caris（CAI）2026 年第一季度财报电话会议记录</li>
<li>中性情绪：关于该股下跌的报道反映出更广泛的担忧，即估值仍然偏高，市场可能更关注预期和指引，而非强劲的收入超预期。为什么 Caris Life Sciences, Inc.（CAI）的股价下跌了 18.04%</li>
<li>消极情绪：多位分析师在报告后下调了目标价，包括花旗至 28 美元、摩根大通至 30 美元和 BTIG 至 32 美元，这可能对情绪产生了影响，尽管所有分析师都维持了积极评级。分析师目标价变动</li>
</ul>
</div><h2>Institutional Trading of Caris Life Sciences</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG boosted its position in Caris Life Sciences by 825.9% during the fourth quarter. UBS Group AG now owns 2,183,980 shares of the company's stock valued at $58,924,000 after purchasing an additional 1,948,107 shares during the last quarter. Zevenbergen Capital Investments LLC acquired a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $14,655,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Caris Life Sciences during the 4th quarter worth approximately $3,942,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $1,584,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $2,498,000.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近修改了对该股的持仓。瑞银集团在第四季度将其在 Caris Life Sciences 的持仓增加了 825.9%。瑞银集团目前拥有 2183980 股该公司的股票，价值 58924000 美元，此前在上个季度购买了 1948107 股。Zevenbergen Capital Investments LLC 在第四季度新建了对 Caris Life Sciences 的持仓，价值约 14655000 美元。德凯银行在第四季度购买了价值约 3942000 美元的 Caris Life Sciences 新股份。Hamilton Lane Advisors LLC 在第四季度新建了对 Caris Life Sciences 的持仓，价值约 1584000 美元。最后，TD Waterhouse Canada Inc.在第四季度新建了对 Caris Life Sciences 的持仓，价值约 2498000 美元。</p>
</div><h2>Caris Life Sciences Price Performance</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的价格表现</h2>
</div><p>The stock has a market capitalization of $4.56 billion and a price-to-earnings ratio of -2.12. The company's 50 day simple moving average is $19.15. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35.</p>
<div class="lb-trans"><p>该股市值为 45.6 亿美元，市盈率为-2.12。该公司的 50 日简单移动平均线为 19.15 美元。公司的债务与股本比率为 0.66，流动比率为 7.85，速动比率为 7.35。</p>
</div><p>Caris Life Sciences (NASDAQ:CAI - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.27. Caris Life Sciences had a net margin of 3.75% and a return on equity of 102.71%. The firm had revenue of $292.89 million for the quarter, compared to analyst estimates of $281.00 million. During the same period in the prior year, the firm posted ($1.73) earnings per share. The company's quarterly revenue was up 125.4% compared to the same quarter last year. Analysts anticipate that Caris Life Sciences, Inc. will post 0.12 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Caris Life Sciences（纳斯达克代码：CAI - 获取免费报告）最后一次发布季度财报是在 2 月 26 日，报告显示该季度每股收益（EPS）为 0.28 美元，超出市场共识预期的 0.01 美元，超出幅度为 0.27 美元。Caris Life Sciences 的净利润率为 3.75%，股本回报率为 102.71%。该公司该季度的收入为 2.9289 亿美元，而分析师预期为 2.81 亿美元。在去年同期，该公司的每股收益为-1.73 美元。该公司的季度收入同比增长 125.4%。分析师预计 Caris Life Sciences, Inc.在本财年将发布 0.12 美元的每股收益。</p>
</div><h2>About Caris Life Sciences</h2>
<div class="lb-trans"><h2>关于 Caris Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.</p>
<div class="lb-trans"><p>Caris Life Sciences（纳斯达克代码：CAI）是一家分子科学公司，专注于推动肿瘤学中的精准医学。该公司开发并提供全面的分子分析服务，旨在识别 DNA、RNA 和蛋白质模式中的可操作生物标志物。其临床服务旨在通过根据肿瘤生物学将患者与靶向疗法、免疫疗法和相关临床试验匹配，来支持肿瘤科医生的治疗决策。</p>
</div><p>Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.</p>
<div class="lb-trans"><p>Caris 提供基于实验室的诊断测试和相关的解释报告，将高通量测序和其他分子技术与生物信息学分析相结合。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Caris Life Sciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Caris Life Sciences</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Caris Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Caris Life Sciences 吗？</h2>
</div><p>Before you consider Caris Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Caris Life Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caris Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Caris Life Sciences 并不在名单上。</p>
</div><p>While Caris Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Caris Life Sciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Caris Life Sciences (NASDAQ:CAI) Hits New 52-Week Low After Analyst Downgrade

Market Beat

Caris Life Sciences

基因改革 ETF - ARK

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

美国医药设备 ETF - iShares

标普生物技术 3 倍做多 - Direxion

基因免疫&健康关怀 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

美国医疗保健供应商 ETF - iShares

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

花旗

Piper Sandler Cos

摩根大通

瑞银集团

Hamilton Lane 

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Caris Life Sciences（纳斯达克股票代码：CAI）在分析师下调评级后跌至 52 周新低